secwatch.observer — SEC 8-K summary
======================================

Issuer:     Connect Biopharma Holdings Ltd (CNTB)
CIK:        0001835268
Form:       8-K
Filed at:   2025-05-13T23:59:59+00:00
Accession:  0001835268-25-000026
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Connect Biopharma initiates Phase 2 Seabreeze STAT study of rademikibart for acute asthma exacerbations
--------------------------------------------------------------------------------

- Phase 2 Seabreeze STAT Asthma study (NCT06940141) initiated after FDA agreement on final protocol.
- Evaluates rademikibart as adjunct to standard of care in ~160 adults/adolescents with type 2 inflammation asthma.
- Primary endpoint: treatment failure rate over 28 days; secondary include exacerbations and lung function.
- Topline data expected in first half of 2026.
- Imminently on track to initiate a similarly-designed Phase 2 study in COPD.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1835268/000183526825000026/0001835268-25-000026-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1835268/000183526825000026/cntb-20250513.htm
  HTML page:      https://secwatch.observer/filing/0001835268-25-000026

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer